Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 30 recruiting now early-phase tilt

Pancreas Cancer: early-phase trial registry

30 of 55 indexed Pancreas Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #254 of 28,707 conditions by registered trial count.

55 US clinical trials · 30 currently recruiting · #254 of 28,707 conditions by registered trial count

Pancreas Cancer: 55 US clinical trials tracked, 30 recruiting.

Pancreas Cancer is the subject of 55 registered US clinical trials on ClinicalTrials.gov, 30 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 29 in Phase 1-2 (earlier-stage). The most active sponsor is A2 Biotherapeutics, running 3 of these trials.

Enrollment posture brief

Registry condition pancreas-cancer

OPEN 30 | RECR 55% | LATE 2 | EARLY 29 | RANK #254 | SPON 3

Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)

Pancreas Cancer (this)55%Colorectal Neoplasms41.8%Down Syndrome38.2%Constipation27.3%Brain and Central Nervous Sy1.8%
Open-enrollment share among volume-matched conditions near Pancreas Cancer

Pancreas Cancer lists 30 open slots (55% of 55 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Pancreas Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Pancreas Cancer is recruiting above its size-band peers.

    30 of 55 indexed trials (54.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Pancreas Cancer trials is spread across many organizations.

    A2 Biotherapeutics accounts for 3 of 55 trials (5.5%). 41 distinct sponsors appear on at least one study for this condition label.

  3. Typical Pancreas Cancer enrolment sits around 60 participants.

    Median target enrolment is 60 among the 55 trials that report a genuine target (sentinel values excluded). 32 of those (58.2%) plan for fewer than 100 participants.

  4. Pancreas Cancer research is mostly interventional.

    42 interventional and 13 observational studies make up this index (76.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 121Phase 28Phase 32

Phase Distribution

PhaseTrial count
Phase 1 21
Phase 2 8
Phase 3 2

Named interventions

Most-linked intervention names on Pancreas Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Gemcitabine Drug
5 trials
Folfirinox Drug
2 trials
Chemotherapy Drug
2 trials
Sterostatic body radiation therapy (SBRT) Radiation
1 trials
GI-4000 Biological
1 trials
Optimized neoantigen synthetic long peptide vaccine Biological
1 trials
NP-G2-044 Drug
1 trials
IM156 Drug
1 trials

US sites by state

Facility locations filed on Pancreas Cancer trials. A trial with sites in several states counts in each.

California 19 trials
New York 17 trials
Texas 13 trials
Missouri 13 trials
Florida 10 trials
Ohio 9 trials
Massachusetts 8 trials
Arizona 8 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Pancreas Cancer page

55 registered trials, 30 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreas Cancer condition card totals 55 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.